MedRx Co. Ltd. announced consolidated and non-consolidated earnings results for the year ended December 31, 2014. For the year, the group reported net sales of ¥26 million, operating loss of ¥1,003 million, ordinary loss of ¥1,012 million and net loss of ¥1,016 million or ¥151.96 per share compared to net sales of ¥68 million, operating loss of ¥604 million, ordinary loss of ¥616 million and net loss of ¥621 million or ¥113.48 per share reported in the same period last year. Negative return on equity was 25.4% against 26.0% reported last year. Cash used in operating activities was ¥931 million against ¥613 million reported last year.

For the year ending December 31, 2015, the group expected to report net sales of ¥18 million, operating loss of ¥1,035 million, ordinary loss of ¥890 million and net loss of ¥894 million or ¥133.73 per share.

For the six months ending Jun. 2015, the group expected to report net sales of ¥9 million, operating loss of ¥501 million, ordinary loss of ¥374 million and net loss of ¥376 million or ¥56.29 per share.

For the year, the parent company reported net sales of ¥26 million, operating loss of ¥1,010 million, ordinary loss of ¥996 million and net loss of ¥1,001 million or ¥149.70 per diluted share compared to net sales of ¥68 million, operating loss of ¥611 million, ordinary loss of ¥594 million and net loss of ¥598 million or ¥109.25 per diluted share reported in the same period last year.

For the year ending December 31, 2015, the parent company expected to report net sales of ¥18 million, ordinary loss of ¥898 million and net loss of ¥902 million or ¥134.98 per share.

For the six months ending Jun. 2015, the parent company expected to report net sales of ¥9 million, ordinary loss of ¥366 million and net loss of ¥368 million or ¥55.08 per share.